Back to Search
Start Over
In vitro selection of DNA aptamers recognizing drug-resistant ovarian cancer by cell-SELEX
- Source :
- Talanta. 194:437-445
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Ovarian cancer is regarded as the most lethal gynecologic malignancy with poor prognosis and high mortality rate. Drug-resistance was thought to be the main obstacle to improving overall survival rate of ovarian cancer. New ligands for drug-resistant ovarian cancer cells have potential for the development of diagnosis and therapy of ovarian cancer. In present work, we reported two aptamers, HF3-58 and HA5-68 generated by cell-SELEX, against a paclitaxel-resistant ovarian cancer cell line (A2780T). Both two aptamers exhibited high selectivity and strong affinity to target cells with low nanomolar dissociation constants. The binding of aptamers to target cells was independent of divalent ions, and was tolerant of incubation temperature and nucleases in serum. Molecular targets of the two aptamers were preliminarily demonstrated to be two different glycoproteins on cell surface of A2780T cells. Owing to the structure stability and high resistance to nuclease, these two aptamers had good performance in the detection of drug-resistant ovarian cancer cells in human serum.
- Subjects :
- Aptamer
Cell
02 engineering and technology
Drug resistance
01 natural sciences
Analytical Chemistry
Cell Line, Tumor
medicine
Humans
Ovarian Neoplasms
chemistry.chemical_classification
Nuclease
Base Sequence
biology
Chemistry
Cell Membrane
SELEX Aptamer Technique
010401 analytical chemistry
Aptamers, Nucleotide
021001 nanoscience & nanotechnology
medicine.disease
In vitro
0104 chemical sciences
medicine.anatomical_structure
Drug Resistance, Neoplasm
Cancer research
biology.protein
Female
0210 nano-technology
Molecular probe
Glycoprotein
Ovarian cancer
Subjects
Details
- ISSN :
- 00399140
- Volume :
- 194
- Database :
- OpenAIRE
- Journal :
- Talanta
- Accession number :
- edsair.doi.dedup.....ace8fbc6540916aba52f1b5c616ac2f9